The Change of Serum Copper and Zinc Levels in Patients with Chronic Obstructive Pulmonary Disease and Its Function_West China Medical Journal

Authors：

ZUO Qiunan ¹ , ZHAO Li ¹ , WANG Ye ² ,  WEN Fuqiang ¹

1. Department of Respiratory Medicine; 2. Department of Internal Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

WEN Fuqiang, Email: 179538224@qq.com

Keywords：

微量元素; 炎症因子; 氧化失衡; 慢性阻塞性肺疾病; 金属硫蛋白

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　探讨慢性阻塞性肺疾病（COPD）患者中微量元素铜和锌与炎症介质的关系。方法　2010年11月－2011年3月间测量15例COPD急性加重期患者入院时及治疗后和13例健康者为对照组的血清铜、锌、C反应蛋白（CRP）、白介素-6（IL-6），血浆中金属硫蛋白，以及氧化应激产物丙二醛的浓度变化。并对铜、锌浓度变化与CRP、IL-6进行相关分析。结果　COPD组血清中铜浓度、CRP、IL-6水平高于对照组（P＜0.05），同时急性加重期患者血清中铜的浓度、CRP、IL-6水平以及丙二醛值高于缓解期患者（P＜0.05）。而急性加重期患者血清中锌浓度低于缓解期组和对照组（P＜0.05）。血浆中抗氧化物质金属硫蛋白在三组间差异无统计学意义（P＞0.05）。在微量元素与炎症因子的相关分析中发现，铜与CRP（r=0.602，P＜0.001）、IL-6（r=0.533，P＜0.001）呈正相关，锌与IL-6呈负相关（r=?0.336，P＜0.05）。结论　在COPD氧化应激发病机制中，铜可能发挥促氧化应激的作用，而锌可能发挥抗氧化应激的作用。微量元素稳态的紊乱有可能是COPD急性加重的危险因素。

Citation： ZUO Qiunan,ZHAO Li,WANG Ye,WEN Fuqiang. The Change of Serum Copper and Zinc Levels in Patients with Chronic Obstructive Pulmonary Disease and Its Function. West China Medical Journal, 2012, 27(4): 517-520. doi: Copy

1.	Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: goble burden of disease study[J]. Lancet, 1997, 349(9064): 1498-1504.
2.	Bai N, Khazaei M, van Eeden SF, et al. The pharmacology of particulate matter air pollution-induced cardiovascular dysfunction[J]. Pharmacol Ther, 2007, 113(1): 16-29.
3.	Decramer M, Celli B, Tashkin DP, et al. Clinial trial design considerations in assessing long term functional impacts of tiotropium in COPD: the UPLIFT trial[J]. COPD, 2004, 1(2): 303-312.
4.	Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group[J]. Am J Respir Crit Care Med, 1997, 156(2 Pt 1): 341-357.
5.	Sato M. Biological antioxidant defence system and metallotheionein[J]. Jpn J Toxicol Environ Health,1992, 38(3):228-239.
6.	Viarengo A, Burlando B, Ceratto N, et al. Antioxidant role of metallothioneins: a comparative overview[J]. Cell Mol Biol, 2000, 46(2): 407-417.
7.	Huang YL, Sheu JY, Lin TH. Association between oxidative stressand changes of trace elements in patients with breast cancer[J].Clin Biochem, 1999, 32(2): 131-136.
8.	Tadzhiev FS. Trace elements in the pathogenesis and treatmentof chronic bronchitis (a clinico-experimental study) [J]. Ter Arkh, 1991, 63(3):68-70.
9.	Karadag F, C?ldag O, Alt?n?s?k M, et al. Trace elements as a component of oxidative stress in COPD[J]. Respirology, 2004, 9(1):33-37.
10.	Volanakis JE. Human C- reactive protein: expression, structure, and function[J]. Mol Immuno, 2001, 38(2-3): 189-197.
11.	Wouters EF. Local and systemic inflammation in chronic obstructivepulmonary disease[J]. Proc Am Thorac Soc, 2005, 2(1): 26-33.
12.	Rahman I, Macnee W. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary diseases[J]. Thorax, 1996, 51(4): 348-350.
13.	Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers [J].Am J Respir Crit Care Med, 1996, 154(4 pt 1): 1055-1060.
14.	Morrison D, Rahman I, Lannan S, et al. Epithelial permeability, in?ammation, and oxidant stress in the air spaces of smokers[J]. Am J Respir Crit Care Med, 1999, 159(2): 473-479.
15.	Rahman I, Skwarska E, MacNee W. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease[J].Thorax, 1997, 52(6): 565-568.
16.	Quilliot D, Dousset B, Guerci B, et al. Evidence that diabetes mellitu favors impaired metabolism of zinc, copper and selenium in chronic pancreatitis[J]. Pancreatitis, 2001, 22(3):299-306.
17.	Fabisiak JP, Tyurin VA, Tyurina YY, et al. Redox regulation of copper-metallothionein[J].Arch Biochem Biophys, 1999, 363(1): 171-181.
18.	Rasad AS. Zinc in human health: an update[J]. Trace Elem Exp Med, 1998, 11(2-3): 63-87.
19.	Kiril G, Hamdi Muz M, Seckin D, et al. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease[J]. Respir Med, 2008, 102(6): 840-844.
20.	Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers[J]. Thorax, 2006, 61(1): 23-28.
21.	Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2007, 175(3): 250-255.
22.	Schols AM, Buuman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangement s and increased levels of inflammatory mediators in a subgroup of patient s with chronic obstructive pulmonary disease[J].Thorax,1996, 51(8): 819-824.
23.	Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2004, 170(7): 760-765.
24.	Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic in?ammation and decline in lung function in patients with COPD[J]. Chest, 2005, 128(4): 1995-2004.
25.	Mocchegiani E, Malavolta1 M, Costarelli L, et al. Zinc, metallothioneins and immunosenescence[J]. Proc Nutr Soc, 2010, 69(3): 290-299.

1. 　Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: goble burden of disease study[J]. Lancet, 1997, 349(9064): 1498-1504.
2. 　Bai N, Khazaei M, van Eeden SF, et al. The pharmacology of particulate matter air pollution-induced cardiovascular dysfunction[J]. Pharmacol Ther, 2007, 113(1): 16-29.
3. 　Decramer M, Celli B, Tashkin DP, et al. Clinial trial design considerations in assessing long term functional impacts of tiotropium in COPD: the UPLIFT trial[J]. COPD, 2004, 1(2): 303-312.
4. 　Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group[J]. Am J Respir Crit Care Med, 1997, 156(2 Pt 1): 341-357.
5. 　Sato M. Biological antioxidant defence system and metallotheionein[J]. Jpn J Toxicol Environ Health,1992, 38(3):228-239.
6. 　Viarengo A, Burlando B, Ceratto N, et al. Antioxidant role of metallothioneins: a comparative overview[J]. Cell Mol Biol, 2000, 46(2): 407-417.
7. 　Huang YL, Sheu JY, Lin TH. Association between oxidative stressand changes of trace elements in patients with breast cancer[J].Clin Biochem, 1999, 32(2): 131-136.
8. 　Tadzhiev FS. Trace elements in the pathogenesis and treatmentof chronic bronchitis (a clinico-experimental study) [J]. Ter Arkh, 1991, 63(3):68-70.
9. 　Karadag F, C?ldag O, Alt?n?s?k M, et al. Trace elements as a component of oxidative stress in COPD[J]. Respirology, 2004, 9(1):33-37.
10. 　Volanakis JE. Human C- reactive protein: expression, structure, and function[J]. Mol Immuno, 2001, 38(2-3): 189-197.
11. 　Wouters EF. Local and systemic inflammation in chronic obstructivepulmonary disease[J]. Proc Am Thorac Soc, 2005, 2(1): 26-33.
12. 　Rahman I, Macnee W. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary diseases[J]. Thorax, 1996, 51(4): 348-350.
13. 　Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers [J].Am J Respir Crit Care Med, 1996, 154(4 pt 1): 1055-1060.
14. 　Morrison D, Rahman I, Lannan S, et al. Epithelial permeability, in?ammation, and oxidant stress in the air spaces of smokers[J]. Am J Respir Crit Care Med, 1999, 159(2): 473-479.
15. 　Rahman I, Skwarska E, MacNee W. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease[J].Thorax, 1997, 52(6): 565-568.
16. 　Quilliot D, Dousset B, Guerci B, et al. Evidence that diabetes mellitu favors impaired metabolism of zinc, copper and selenium in chronic pancreatitis[J]. Pancreatitis, 2001, 22(3):299-306.
17. 　Fabisiak JP, Tyurin VA, Tyurina YY, et al. Redox regulation of copper-metallothionein[J].Arch Biochem Biophys, 1999, 363(1): 171-181.
18. 　Rasad AS. Zinc in human health: an update[J]. Trace Elem Exp Med, 1998, 11(2-3): 63-87.
19. 　Kiril G, Hamdi Muz M, Seckin D, et al. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease[J]. Respir Med, 2008, 102(6): 840-844.
20. 　Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers[J]. Thorax, 2006, 61(1): 23-28.
21. 　Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2007, 175(3): 250-255.
22. 　Schols AM, Buuman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangement s and increased levels of inflammatory mediators in a subgroup of patient s with chronic obstructive pulmonary disease[J].Thorax,1996, 51(8): 819-824.
23. 　Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2004, 170(7): 760-765.
24. 　Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic in?ammation and decline in lung function in patients with COPD[J]. Chest, 2005, 128(4): 1995-2004.
25. 　Mocchegiani E, Malavolta1 M, Costarelli L, et al. Zinc, metallothioneins and immunosenescence[J]. Proc Nutr Soc, 2010, 69(3): 290-299.

West China Medical Journal

The Change of Serum Copper and Zinc Levels in Patients with Chronic Obstructive Pulmonary Disease and Its Function

Abstract Full text Figures/Tables Video References Cited by

Format

Content